Real Life Efficacy and Tolerability of Eslicarbazepine Acetate in Children Aged 6 Years or Older with Focal Epilepsy on Carbamazepine or Oxcarbazepine
Abstract number :
2.151
Submission category :
4. Clinical Epilepsy / 4C. Clinical Treatments
Year :
2023
Submission ID :
516
Source :
www.aesnet.org
Presentation date :
12/3/2023 12:00:00 AM
Published date :
Authors :
Presenting Author: Sooyoung Lyu, MD – Pusan National University Children’s Hospital
Yun-Jin Lee, MD/PhD – Professor, Department of Pediatrics, Pusan National University Children’s Hospital; Juhyun Kong, MD – Professor, Department of Pediatrics, Pusan National University Children’s Hospital; Sang Ook Nam, MD/PhD – Professor, Department of Pediatrics, Pusan National University Children’s Hospital
Rationale:
This study aims to evaluate the influence of prior use of carbamazepine (CBZ) or oxcarbazepine (OXC) and other anti-seizure medications (ASMs) with similar mechanism of action (sodium channel blocker; SCB) on seizure outcomes and tolerability when converting to eslicarbazepine acetate (ESL).
Methods:
Children aged six years or older with focal epilepsy started adjunctive or converting ESL once daily. The primary endpoints included change in seizure frequency, responder rate, and safety. Endpoints were analyzed for subgroups of patients who received CBZ/OXC (or any SCB) during baseline versus those who received other ASMs.
Results:
Of 69 patients in the studies, 52 were evaluable for efficacy. When starting adjunctive ESL or converting to ESL, the risk of study exit of worsening seizure was not significantly higher with baseline use of CBZ/OXC (p=0.10) or other SCB (p=0.33). Reductions in seizure frequency and responder rates were not meaningfully lower in patients who converted from CBZ/OXC or other SCB (49.4% vs 41.3%, p=0.35) compared with those who converted from other ASMs (49.4% vs 42.7%, p=0.41). There were no notable differences in overall tolerability between subgroups, but the incidence of some adverse events (e.g., dizziness, somnolence, nausea) varied between subgroups and/or between treatment periods.
Conclusions:
Baseline use of CBZ/OXC or other major SCBs did not appear to significantly increase the risk of worsening seizure, or to increased adverse events when starting adjunctive ESL or converting to ESL monotherapy. ESL adjunctive therapy or converting monotherapy was efficacious and tolerated in children aged six years or older with focal epilepsy regardless of previous CBZ/OXC used in combination.
Funding: The authors declare no competing financial interests.
Clinical Epilepsy